EISAI CO

The FDA has cleared SEED Therapeutics' IND application for ST-01156, a molecular glue degrader targeting RBM39, enabling a Phase 1 trial in advanced solid tumor and hematological malignancies.

Roche announced plans to test Trontinemab, an experimental drug designed to delay or prevent Alzheimer's disease symptoms in at-risk individuals.

Eisai Thailand has launched Beova® Tablets (vibegron), a selective β3-adrenergic receptor agonist for overactive bladder treatment, marking the first market entry in Eisai's licensed ASEAN region.

Biogen presents 48-month data from LEQEMBI's Clarity AD open-label extension study and introduces subcutaneous formulation for maintenance dosing at AAIC 2025.

BeyondSpring's Plinabulin combined with radiation and PD-1 inhibitors achieved a 23% overall response rate and 54% disease control rate in patients who failed prior checkpoint inhibitor therapy.

Total M&A deal value in Alzheimer's disease jumped from $2 billion in 2022 to $18 billion in 2024, representing a 780% increase following the approval of disease-modifying treatments.

A multicenter retrospective study of 108 patients demonstrated that tislelizumab, with or without tyrosine kinase inhibitors, significantly extended recurrence-free survival in high-risk hepatocellular carcinoma patients after curative resection.

Biogen reported Leqembi generated $160 million in global sales for Q2 2024, representing a 58% increase, with U.S. sales rising 20% to $63 million despite ongoing market adoption challenges.

The National Institute for Health and Care Excellence (NICE) has refused to recommend lecanemab and donanemab for NHS use, denying access to over 70,000 eligible patients in England unless they can afford private treatment costing £60,000-80,000 annually.

Gyre Therapeutics has successfully dosed the first volunteer in a Phase 1 clinical trial evaluating F230, a novel endothelin A receptor antagonist, for treating pulmonary arterial hypertension in China.